Fig 1: MET and HER2 expression levels in 033 T tumor sample. a Brain MRI showed a relatively well-demarcated enhancing mass in right frontal lobe. b Chest CT showed multiple masses, measuring up to 4 cm, in 033 T patient. c Genomic profiling of focal amplifications in 033 T patient derived tumor, PDXs, and PDX cells identified focal gains of MET and HER2. d Quantitative polymerase chain reaction gene copy number analysis was performed in order to detect MET and HER2 amplifications. NC; patient 694 T samples, used as negative controls, did not show MET and HER2 amplification. e MET, HER2, phosphorylated MET, phosphorylated HER2, and GAPDH as a loading control were analyzed using western blot. f Histologic comparison between the patient tumor sample and PDX tumor. The representative areas of each patient tumor sample and the corresponding PDXs were stained with H&E, MET, and HER2 antibodies. Fluorescence in situ hybridization of MET revealed amplification in many tumor cells (red dots). Silver in situ hybridization of HER2 showed amplification of HER2 in the patient tumor sample and PDX tumor (black dots). MET and HER2 immunohistochemical staining showed distinctive expression patterns in the patient-derived sample and PDX tumor sample (MET, HER2, ×200)
Fig 2: Identification of MET and HER2 amplifications in lung cancers. The analysis of focal amplifications in lung adenocarcinoma (LUAD; n = 494) and lung squamous cell carcinoma (LUSC; n = 492). The Cancer Genomic Atlas samples identify focal gains of MET and HER2 that are specific to the LUAD
Fig 3: Positivity (score 3) for the four HER2 antibodies (A0485, SP3, pHER2Y877, and pHER2Y1248) and HER2 amplification by CISH in peritoneal disseminated cancer cells of HGSOC.
Fig 4: Hsp90 correlated with PD-L1 and HER2 expression in HPV16+ cervical cancer. A PD-L1 and HER2 gene expression in normal and cancer tissues. B correlation analysis among Hsp90, PD-L1 and HER2 expression in normal and cancer tissues. C PD-L1 and HER2 gene expression in normal (H8) and cancer (Caski and SiHa) cervical epithelial cell lines. D Western blot of PD-L1 and HER2 expression in normal (H8) and cancer (Caski and SiHa) cervical epithelial cell lines. Clinical samples: N = 25 in normal tissue group, N = 38 of cancer tissue group. *p < 0.05. Cell culture study: N = 3 in each group. *p < 0.05 or **p < 0.01
Fig 5: HER2 CISH and HER2 immunohistochemical staining in peritoneal disseminated cancer cells of HGSOC using four anti-HER2 antibodies: A0485, SP3, pHER2Y877, and pHER2Y1248 (A–J). Cases 22 and 29 showed positive HER2 amplification (I,J). Original magnification, 600×. Case 22 shows positive HER2 expression using all four anti-HER2 antibodies (A,C,E,G), and case 29 was positive using three antibodies (A0485, SP3, and pHER2Y1248) (B,D,H). Original magnification, 400×.
Supplier Page from Abcam for Anti-ErbB2 / HER2 (phospho Y877) antibody [EP2324Y]